Circulating Tumor Cell Isolation Devices
Revolutionize cancer diagnostics and precision oncology with Angle’s FDA-approved Parsortix® system, a breakthrough in circulating tumor cell (CTC) isolation. This advanced technology enables highly specific, label-free enrichment of viable CTCs from patient blood samples, providing an accurate, non-invasive liquid biopsy solution for early cancer detection, disease progression monitoring, and real-time treatment assessment.
Unlike traditional biopsy methods, the Parsortix® system captures intact, viable CTCs, preserving their biological integrity for downstream molecular, genomic, and functional analysis. By offering a repeatable and minimally invasive approach, this technology enhances personalized treatment strategies, supporting targeted therapy decisions and improving patient outcomes.
Key benefits include:
- Efficient, high-purity CTC recovery for downstream molecular profiling.
- Non-invasive, repeatable liquid biopsy for real-time cancer monitoring.
- Compatible with single-cell analysis, genomic sequencing, and drug sensitivity testing.
- Validated for clinical and translational research, enhancing precision medicine.
Unlock the potential of circulating tumor cell analysis and take oncology diagnostics to the next level.
